{
  "meta": {
    "title": "全球IVD测试市场 · Kalorama 第19版 行业锚点库",
    "source": "Kalorama Information《The Worldwide Market for IVD Tests, 19th Edition》2026年5月 · 1171页",
    "unit": "百万美元",
    "updated": "2026-09-12",
    "note": "数据为报告原文口径，仅用于客户沟通的行业锚点。报告为人用IVD口径，宠物诊断/食品安全检测/科研服务不在其分段内。",
    "fulltext": "知识库-copilot/公用/市场动态/_全文/全球IVD测试市场19版_全文.txt.gz",
    "readpage": "销售分析/行业研究_全球IVD测试市场19版_精读_2026.html",
    "factcard": "知识库-copilot/公用/市场动态/行业_全球IVD测试市场19版_事实卡.md"
  },
  "global": {
    "name": "全球IVD测试市场",
    "y2025": 115559,
    "y2030": 150446,
    "cagr": 5.4,
    "extra": "TOP20厂商占近80%（2025年920亿）；2024→2025实际增长约5%"
  },
  "china": {
    "name": "中国IVD市场",
    "y2025": 5997,
    "y2030": 7361,
    "cagr": 4,
    "global_share": "5%",
    "per_capita_usd": 4.19,
    "structure": "POC合计34%｜临床生化12%｜免疫其它9%｜微生物ID/AST8%｜免疫传染病8%｜血液学8%｜分子微生物5%｜组织学5%｜凝血3%｜血筛分子2%",
    "hospital_density": "0.9家/10万人（日本>7、韩国3.42）; 独立实验室仅占市场值2%、约110家且多数无CNAS认可",
    "vbp": "集采（VBP）+DRG/DIP压价；报告结论：长期看好差异化、高值、不受VBP影响的产品",
    "quote": "报告称中国为「显著未被满足的市场」"
  },
  "segments": {
    "poc_pro": {
      "name": "POC 专业",
      "y2025": 13537,
      "y2030": 16751,
      "cagr": 4
    },
    "imm_infect": {
      "name": "免疫—传染病",
      "y2025": 13165,
      "y2030": 15494,
      "cagr": 3
    },
    "imm_other": {
      "name": "免疫—其它（非感染）",
      "y2025": 12610,
      "y2030": 15267,
      "cagr": 4
    },
    "cgm": {
      "name": "连续血糖 CGM",
      "y2025": 12458,
      "y2030": 20600,
      "cagr": 11,
      "g24_25": 16.1
    },
    "chem": {
      "name": "临床生化",
      "y2025": 10978,
      "y2030": 13308,
      "cagr": 4
    },
    "mol_micro": {
      "name": "分子微生物",
      "y2025": 8672,
      "y2030": 10631,
      "cagr": 4
    },
    "poc_otc_glu": {
      "name": "POC OTC 血糖",
      "y2025": 6693,
      "y2030": 7020,
      "cagr": 1
    },
    "micro_id": {
      "name": "微生物 ID/AST",
      "y2025": 5586,
      "y2030": 6314,
      "cagr": 2
    },
    "hema": {
      "name": "血液学",
      "y2025": 5495,
      "y2030": 7455,
      "cagr": 6,
      "g24_25": 7.3
    },
    "histo": {
      "name": "组织/细胞学",
      "y2025": 5017,
      "y2030": 6597,
      "cagr": 6
    },
    "mol_onco": {
      "name": "分子肿瘤",
      "y2025": 4705,
      "y2030": 9500,
      "cagr": 15,
      "note": "MRD 微小残留病灶 / ctDNA 高灵敏检测"
    },
    "poc_otc_other": {
      "name": "POC OTC 其它",
      "y2025": 3642,
      "y2030": 4489,
      "cagr": 4
    },
    "coag": {
      "name": "凝血",
      "y2025": 1794,
      "y2030": 2098,
      "cagr": 3
    },
    "ddimer": {
      "name": "D-二聚体",
      "y2025": 1475,
      "y2030": 1710,
      "cagr": 3
    },
    "hba1c": {
      "name": "糖化血红蛋白（实验室）",
      "y2025": 1342,
      "y2030": 1700,
      "cagr": 5
    },
    "mol_gen": {
      "name": "分子遗传/遗传病",
      "y2025": 1332,
      "y2030": 1950,
      "cagr": 8
    },
    "blood_mol": {
      "name": "血站分子（核酸血筛）",
      "y2025": 1330,
      "y2030": 1790,
      "cagr": 6
    },
    "hpv": {
      "name": "HPV 分子",
      "y2025": 1270,
      "y2030": 2145,
      "cagr": 11,
      "g24_25": 12.3
    },
    "bloodtype": {
      "name": "血型",
      "y2025": 1045,
      "y2030": 1150,
      "cagr": 2
    },
    "ms": {
      "name": "质谱",
      "y2025": 1032,
      "y2030": 1580,
      "cagr": 9,
      "g24_25": 6.3
    },
    "blood_screen": {
      "name": "血站筛查",
      "y2025": 834,
      "y2030": 885,
      "cagr": 1
    },
    "drugs": {
      "name": "滥用药物",
      "y2025": 333,
      "y2030": 353,
      "cagr": 1
    },
    "ctc": {
      "name": "循环肿瘤细胞",
      "y2025": 152,
      "y2030": 185,
      "cagr": 4
    },
    "other": {
      "name": "其它",
      "y2025": 1062,
      "y2030": 1474,
      "cagr": 7
    },
    "naat": {
      "name": "核酸扩增 NAAT",
      "cagr": 13.7,
      "note": "报告口径的分子增长引擎，单列未计入分段总额"
    },
    "mol_tx": {
      "name": "分子移植",
      "cagr": 10,
      "note": "报告单列"
    },
    "sepsis": {
      "name": "脓毒症快速检测",
      "cagr": 14,
      "note": "报告单列"
    },
    "clin_seq": {
      "name": "临床测序",
      "y2025": 7505,
      "y2030": 11550,
      "cagr": 9,
      "note": "报告单列，未计入总额"
    },
    "flow": {
      "name": "流式细胞",
      "y2025": 1765,
      "cagr": 5,
      "note": "报告单列"
    },
    "dtc": {
      "name": "DTC 消费级基因检测",
      "y2025": 1195,
      "y2030": 1970,
      "cagr": 11,
      "note": "报告单列"
    },
    "prenatal": {
      "name": "产前检测服务",
      "y2025": 1040,
      "cagr": 8,
      "note": "报告单列"
    },
    "covid": {
      "name": "新冠检测",
      "y2025": 4727,
      "y2030": 5090,
      "cagr": 1,
      "note": "报告单列，未计入总额"
    }
  },
  "tracks": {
    "分子诊断": {
      "label": "分子诊断（核酸扩增 · PCR）",
      "anchor": "naat",
      "segs": [
        "naat",
        "mol_onco",
        "hpv",
        "mol_gen",
        "mol_micro",
        "blood_mol"
      ],
      "entry": "高灵敏分子的核心耗材是酶：高保真、抗抑制、冻干耐受 —— 对应 AcuGenix / FastAmpli / Hyperstart 系列",
      "opp": "分子肿瘤15%、HPV11%、分子遗传8%、核酸扩增13.7% 全部跑赢大盘5.4%；分子微生物全球 86.7 亿美元仍是最大分子分段"
    },
    "免疫诊断": {
      "label": "免疫诊断（化学发光 / 酶免）",
      "anchor": "imm_other",
      "segs": [
        "imm_other",
        "imm_infect",
        "hba1c"
      ],
      "entry": "抗原抗体、酶标记物、稳定体系与批间一致性",
      "opp": "免疫—其它 126.1亿→152.7亿（4%），非感染免疫 2024→2025 实增5.3%，是存量最大盘"
    },
    "临床生化": {
      "label": "临床生化",
      "anchor": "chem",
      "segs": [
        "chem",
        "hba1c"
      ],
      "entry": "生化酶、底物、校准品原料",
      "opp": "临床生化 109.8亿→133.1亿（4%）；中国结构里生化占12%，是本土装机量最大科室"
    },
    "POCT": {
      "label": "POCT / 快速检测",
      "anchor": "poc_pro",
      "segs": [
        "poc_pro",
        "poc_otc_other",
        "cgm",
        "poc_otc_glu"
      ],
      "entry": "冻干工艺服务 + 常温运输体系（不加冷链才能下沉基层）",
      "opp": "POC专业 135.4亿→167.5亿（4%）；中国 POC 合计占34%、人均IVD支出仅4.19美元 → 快速检测+冻干是刚需场景；CGM 11% 是全表增速第二"
    },
    "血液学": {
      "label": "血液学",
      "anchor": "hema",
      "segs": [
        "hema",
        "bloodtype"
      ],
      "entry": "血细胞分析配套试剂与质控原料",
      "opp": "血液学 55.0亿→74.6亿（6%，高于大盘），2024→2025 实增7.3%"
    },
    "微生物": {
      "label": "微生物（鉴定 / 药敏）",
      "anchor": "micro_id",
      "segs": [
        "micro_id",
        "mol_micro",
        "sepsis"
      ],
      "entry": "微生物分子检测（PCR/等温）原料与酶体系",
      "opp": "ID/AST 55.9亿→63.1亿（2%）拖后腿，但分子微生物 4%、脓毒症快速检测 14% —— 结构性机会在分子侧；中国分子微生物仅占5%（美国9.2%），渗透空间最大"
    },
    "凝血": {
      "label": "凝血 / 血栓",
      "anchor": "coag",
      "segs": [
        "coag",
        "ddimer"
      ],
      "entry": "凝血酶、显色底物、质控血浆",
      "opp": "凝血 17.9亿→21.0亿（3%），D-二聚体 14.8亿→17.1亿（3%），均为大盘以下"
    },
    "质谱": {
      "label": "质谱（临床质谱）",
      "anchor": "ms",
      "segs": [
        "ms",
        "micro_id"
      ],
      "entry": "质谱前处理试剂、内标、蛋白酶",
      "opp": "质谱 10.3亿→15.8亿（9%，大盘1.7倍），2024→2025 实增6.3%"
    },
    "组织病理": {
      "label": "组织 / 细胞学",
      "anchor": "histo",
      "segs": [
        "histo"
      ],
      "entry": "病理前处理、染色与分子病理配套",
      "opp": "组织/细胞学 50.2亿→66.0亿（6%），高于大盘"
    },
    "血筛": {
      "label": "血筛 / 输血（核酸血筛 NAT）",
      "anchor": "blood_mol",
      "segs": [
        "blood_mol",
        "blood_screen",
        "bloodtype"
      ],
      "entry": "血筛多重PCR/等温体系原料（Tth、UNG、dNTP）",
      "opp": "血站分子 13.3亿→17.9亿（6%）；血站筛查 8.34 亿美元仅 1% 增长 —— 增量在「分子替代血清学」而非总量"
    },
    "第三方检验": {
      "label": "第三方医学检验（ICL）",
      "anchor": "clin_seq",
      "segs": [
        "clin_seq",
        "prenatal",
        "dtc",
        "flow",
        "mol_onco"
      ],
      "entry": "上机前处理原料 + 冻干预混液（ICL 走量、对单价极敏感）",
      "opp": "临床测序 75.1亿→115.5亿（9%）；中国独立实验室仅占市场值2%、约110家且多数无CNAS —— 集中度极低=跑量空间"
    },
    "临床测序": {
      "label": "临床测序 / NGS",
      "anchor": "clin_seq",
      "segs": [
        "clin_seq",
        "mol_gen",
        "mol_onco",
        "dtc"
      ],
      "entry": "建库酶、逆转录酶、文库定量原料",
      "opp": "临床测序 9%、DTC基因检测 11%、分子遗传 8%；中国占全球临床基因检测实验室约10%、科研/应用型NGS系统约15%"
    },
    "多平台综合": {
      "label": "多平台综合（生化+免疫+分子）",
      "anchor": "mol_onco",
      "segs": [
        "chem",
        "imm_other",
        "naat",
        "mol_onco",
        "poc_pro"
      ],
      "entry": "按平台分线铺料：分子线跑增速、生化免疫线守存量",
      "opp": "客户多平台并存时，分子线（15%/13.7%/11%）负责增量，生化免疫线（4%/3%）负责基本盘"
    },
    "宠物诊断": {
      "label": "宠物 / 兽医诊断（不在本报告口径）",
      "anchor": "poc_pro",
      "segs": [
        "poc_pro",
        "naat",
        "mol_micro"
      ],
      "entry": "冻干PCR试剂 + 常温运输（宠物医院无冷链、单店量小）",
      "opp": "Kalorama 第19版为人用IVD口径，不含兽医/宠物分段 —— 沟通时以上述人用分段做参照，不可直接引用为宠物市场数据"
    },
    "食品安全": {
      "label": "食品安全检测（不在本报告口径）",
      "anchor": "naat",
      "segs": [
        "naat",
        "mol_micro"
      ],
      "entry": "食源性致病菌 PCR / 等温扩增原料",
      "opp": "Kalorama 第19版不含食品安全检测分段 —— 只能引用分子扩增增速（13.7%）与分子微生物分段作为技术侧参照"
    },
    "科研服务": {
      "label": "科研服务 / CRO（不在本报告口径）",
      "anchor": "clin_seq",
      "segs": [
        "clin_seq",
        "dtc",
        "flow"
      ],
      "entry": "建库/逆转录/文库定量与质谱前处理原料",
      "opp": "Kalorama 第19版为临床IVD口径，科研服务（多组学/测序服务）不在分段内 —— 参照临床测序9%与流式细胞5%的技术趋势"
    },
    "待确认": {
      "label": "赛道待确认",
      "anchor": "naat",
      "segs": [
        "naat",
        "mol_onco",
        "hpv",
        "poc_pro"
      ],
      "entry": "先确认客户终端赛道再定锚点",
      "opp": "暂无该客户终端赛道的确证信息 —— 以下以分子侧高增速分段作为参照，拜访时请核实客户终端产品方向"
    }
  },
  "overrides": [
    {
      "match": [
        "迪安生物"
      ],
      "track": "分子诊断",
      "basis": "宝锐实际购买主体为迪安生物（自产试剂子公司）：分子诊断试剂原料"
    },
    {
      "match": [
        "迪安医学检验"
      ],
      "track": "第三方检验",
      "basis": "第三方医学检验（ICL）——非宝锐采购主体，仅作赛道参照"
    },
    {
      "match": [
        "迈克生物"
      ],
      "track": "多平台综合",
      "basis": "公开产品线：生化+免疫+分子诊断全平台（2025营收21.7亿）"
    },
    {
      "match": [
        "广州万孚",
        "万孚生物"
      ],
      "track": "POCT",
      "basis": "公开业务：POCT快速检测龙头（多平台，含分子）"
    },
    {
      "match": [
        "新产业"
      ],
      "track": "免疫诊断",
      "basis": "公开业务：化学发光国产龙头（化学发光占营收72%）+ 分子Molecision早期"
    },
    {
      "match": [
        "丽珠试剂",
        "珠海丽珠试剂"
      ],
      "track": "血筛",
      "basis": "公开业务：HIV核酸血筛+分子诊断（HIV检测国产前二）"
    },
    {
      "match": [
        "华益美"
      ],
      "track": "血筛",
      "basis": "公开业务：血源病原体核酸筛查（血筛NAT，第五代单管四合一）"
    },
    {
      "match": [
        "上海之江",
        "之江生物"
      ],
      "track": "分子诊断",
      "basis": "公开业务：感染性疾病分子诊断（300+基因诊断产品）"
    },
    {
      "match": [
        "伯杰"
      ],
      "track": "分子诊断",
      "basis": "公开业务：呼吸道/传染病分子诊断试剂"
    },
    {
      "match": [
        "卓诚惠生"
      ],
      "track": "分子诊断",
      "basis": "公开业务：病原微生物分子检测试剂"
    },
    {
      "match": [
        "宏微特斯"
      ],
      "track": "分子诊断",
      "basis": "公开业务：分子POCT（便携PCR）+冻干试剂"
    },
    {
      "match": [
        "佰奥莱博"
      ],
      "track": "宠物诊断",
      "basis": "公开业务：宠物分子诊断PCR仪器+冻干试剂（农业农村部兽药GMP）"
    },
    {
      "match": [
        "西诺通科"
      ],
      "track": "食品安全",
      "basis": "公开业务：食品安全检测试剂/方案（海关、CDC、市场监管局）"
    },
    {
      "match": [
        "欧易"
      ],
      "track": "科研服务",
      "basis": "公开业务：多组学科研服务（蛋白/代谢/单细胞/空间组学）"
    },
    {
      "match": [
        "鲲鹏基因"
      ],
      "track": "分子诊断",
      "basis": "公开业务：分子POCT仪器与配套试剂"
    },
    {
      "match": [
        "透景"
      ],
      "track": "分子诊断",
      "basis": "公开业务：流式荧光免疫+分子诊断（ARMS基因分型原料在采）"
    },
    {
      "match": [
        "中普康睿"
      ],
      "track": "分子诊断",
      "basis": "在采产品：ARMS 基因分型酶/Premix（分子诊断基因分型方向）"
    },
    {
      "match": [
        "天津知因"
      ],
      "track": "分子诊断",
      "basis": "在采产品：RT Premix / Robustart Taq（分子诊断酶原料）"
    }
  ],
  "product_rules": [
    {
      "kw": [
        "qPCR",
        "qRT",
        "PCR",
        "Taq",
        "Premix",
        "RTase",
        "逆转录",
        "UNG",
        "ARMS",
        "dNTP",
        "dATP",
        "核酸",
        "酶",
        "Buffer",
        "冻干",
        "RT "
      ],
      "track": "分子诊断"
    }
  ],
  "default_track": "分子诊断"
}